

AD \_\_\_\_\_

Award Number: DAMD17-97-1-7013

TITLE: Cyclin D1, Anchorage-Independent Growth and Breast Cancer

PRINCIPAL INVESTIGATOR: Catherine Welsh, M.D.

CONTRACTING ORGANIZATION: University of Miami  
Miami, Florida 33101

REPORT DATE: October 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010403 051

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave Blank)		2. REPORT DATE October 1999		3. REPORT TYPE AND DATES COVERED Annual (15 Sep 98 – 14 Sep 99)
4. TITLE AND SUBTITLE Cyclin D1, Anchorage-Independent Growth and Breast Cancer			5. FUNDING NUMBERS DAMD17-97-1-7013	
6. AUTHORS Welsh, Catherine, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Miami Miami, Florida 33101			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES This report contains colored photos				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) Derangements in the cell cycle machinery contribute to uncontrolled cell growth and tumorigenesis. Regulators of G1 progression including cyclin D1 and the cyclin-dependent kinase inhibitors p21 and p27 appear to be of particular importance in the pathogenesis of breast cancer. We suggest that aggressive breast cancer will involve both (i) overexpression of cyclin D1 and (ii) the failure to undergo a compensatory upregulation of cdk inhibitors. The specific aims are designed to test these hypotheses in cell culture models, nude mice, and breast cancer biopsies. We have generated mouse embryo fibroblasts (MEFs) that stably express a tetracycline-regulated cyclin D1 construct. In contrast to the data in NIH-3T3 cells, there was no compensatory upregulation of p21 in MEFs despite significant overexpression of cyclin D1. This may be due to the acquisition of p53 mutations. In addition, human breast cancer tissues have been analyzed for cyclin D1, p27 and Ki67 expression. Following optimization of p21 staining and analysis, correlation with prognostic factors will be performed.				
14. SUBJECT TERMS  Breast Cancer			15. NUMBER OF PAGES 19	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

☒ In conducting research using animals the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publications No. 86-23, Revised 1985).

☒ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to the NIH Guidelines for Research Involving DNA Molecules.

\_\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Catherine Fullerton 11/9/99  
PI- Signature                      Date

## TABLE OF CONTENTS

Introduction.....	5
Body.....	6
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	9
References.....	10
Figures.....	12

## INTRODUCTION

Proteins that regulate progression through the cell cycle have increasingly been implicated as oncogenes. This is particularly true for those which control progression through the G1 phase, including cyclin D1 and the cyclin-dependent kinase (cdk) inhibitors p21<sup>cip1</sup> (p21) and p27<sup>kip1</sup> (p27). Cyclin D1 upregulation occurs as a result of gene amplification and/or mRNA overexpression in a substantial proportion of human breast cancers (1-5). Overexpression of cyclin D1 in transgenic mice leads to breast hyperplasia and multifocal carcinoma (6). Alternatively, in breast as well as other cancers, the cdk inhibitors appear to function as tumor suppressors. Thus, lower than normal protein levels correlate significantly with tumor aggressiveness, histologic grade, and decreased overall patient survival (7-11).

As positive and negative regulators of proliferation, respectively, the levels of cyclins and cdk inhibitors relative to each other determine whether progression through G1 phase proceeds (12-16). In addition, as key factors controlling G1 progression, all three are regulated by extracellular stimuli, including growth factors and cellular adhesion to the extracellular matrix (17,18). Such actions are responsible for the anchorage- and mitogen-dependence of G1 progression in normal cells. Conversely, anchorage- and mitogen-independence is the hallmark of tumorigenesis.

Whether the aberrant levels of cyclin D1, p21, and p27 result in altered cell cycle progression and subsequent proliferation remains to be established. Overexpression of cyclin D1 in cells can result in similar or even delayed cell cycle kinetics, compared to normal mammary epithelial cells (4, 19, 20). Moreover, the overexpression of cyclin D1 fails to induce anchorage-independent growth, the best in vitro correlate of tumorigenicity. Our preliminary data show that the consequences of cyclin D1 overexpression will be most apparent when examining anchorage-independent growth because that is the condition in which normal levels of cyclin D1 become rate-limiting. In addition, our data show that the overexpression of cyclin D1 in NIH-3T3 cells leads to a compensatory increase in the cdk inhibitor p21, and that this compensatory increase can counteract the expected cyclin D1 effect on anchorage-independent Rb phosphorylation and cell cycle progression. Thus, we proposed that the value of cyclin D1 overexpression as a diagnostic indicator for breast cancer is weakened by the compensatory upregulation of cdk inhibitors (CKIs) that can occur in breast cancer cells. We further suggest that aggressive breast cancer will involve both (i) overexpression of cyclin D1 and (ii) the failure to undergo a compensatory upregulation of cdk inhibitors. The specific aims outlined below are designed to test these hypotheses in cell culture models, nude mice, and breast cancer biopsies. Aim 1 is to show that compensatory upregulation of CKIs negates the effect of cyclin D1 overexpression in inducing anchorage-independent growth. Aim 2 is to determine if compensatory upregulation of CKIs negates the effect of cyclin D1 overexpression on tumor formation. Aim 3 is to determine if the overexpression of cyclin D1 in breast cancer cell lines has a

more pronounced growth effect if the cells have also lost their ability to upregulate CKIs. Aim 4 is to examine the relative expression of cyclin D1 and CKIs in a series of breast cancer biopsies.

## **BODY**

**Aim 1:** Test the hypothesis that the compensatory upregulation of CKIs negates the effect of cyclin D1 overexpression in inducing anchorage-independent growth.

Task 1. Complete characterization of adhesion-dependent phenotype of wild-type, p21, and p27 null mouse embryo fibroblasts (MEFs).

As demonstrated previously in the last report, we have found that both p21-null and p27-null MEFs have partially lost the ability to down-regulate cyclin E-cdk2 activity when stimulated in suspension. However, they retain normal adhesion requirements for cyclin D1 expression, Rb phosphorylation, and cyclin A expression. These cell lines thus exhibit an adhesion-dependent phenotype despite the knock-out of one or the other cdk inhibitors.

Task 2. Obtain tetracycline-cyclin D1 transfectants in mouse embryo fibroblasts. Analyze the tetracycline-cyclin D1 cells (wild-type and knock-out) for their ability to undergo anchorage-independent growth. Compare the rates and extent of Rb phosphorylation, cyclins D1 and A expression, and p21 levels when the transfectants are cultured in the presence and absence of substratum.

At the last progress report, we indicated that MEFs were not efficient in their ability to form stable transfectants. However, we have been able to transfect early passage mouse embryo fibroblasts (MEFs) with a tetracycline-repressible cyclin D1 cDNA and isolate several clones that show tetracycline-regulated expression of cyclin D1. (In this system, tetracycline represses the expression of the ectopic cDNA and removal of tetracycline causes its induction.) The general goal is to determine if the induction of cyclin D1 leads to increased expression of p21 as we observed in NIH-3T3 cells.

We have isolated three distinct clones that show tetracycline-regulated expression of cyclin D1, clones M13, M14 and M18 (Fig 1). The clones differ in the basal level of cyclin D1 expression (observed when cultured in the presence of tetracycline) and in the degree to which cyclin D1 expression is properly adhesion dependent (regulated correctly in clones M13 and M14, but apparently not so in clone M18). Importantly, all three clones show strong induction of cyclin D1 upon removal of tetracycline. p21 expression, as expected from our previous studies (17) is upregulated by culturing the cells in the absence of a substratum. However, p21 expression is not altered by the induction of cyclin D1 (Fig 1, compare p21 levels in the presence and absence of tetracycline). The inability of

cyclin D1 overexpression to alter p21 is seen in both adherent and nonadherent cells from all three clones. Given these unexpected results, the proposed follow-up experiments involving tetracycline-regulated expression of cyclin D1 in MEFs from p21 or p27 null mice are no longer justified (aim 2 in the original application).

**Task 3.** Analyze the mechanism by which cyclin D1 regulates the expression of p21.

There appears to be fundamental differences in the way p21 is influenced by the levels of cyclin D1 in NIH-3T3 cells compared to MEFs. We are considering the possibility that p21 is not being induced because the MEFs are acquiring p53 mutations as a consequence of time in culture. We plan to use the NIH-3T3 cell system to determine if the induction of p21 is due to changes in abundance of its mRNA. This result would support the idea that p53 mutations might be preventing us from seeing the cyclin D1 effect in long-term MEF cultures.

**Aim 2:** Determine if compensatory upregulation of CKIs negates the effect of cyclin D1 overexpression on tumor formation.

As stated above, we observed no changes in the levels of p21 despite potentially inducing cyclin D1 overexpression in MEFs. This lack of effect in MEFs is critical to approaching Aim 2 as this is the cell line where p21- and p27-null cells have been produced. The proposed experiments, to determine the consequences of compensatory p21 upregulation on tumor formation are therefore, no longer justified.

**Aim 3:** Determine if the overexpression of cyclin D1 in breast cancer cell lines has a more pronounced growth effect if the cells have also lost their ability to upregulate cyclin-dependent kinase inhibitors.

**Task 1.** Characterize a series of breast cancer cell lines which overexpress cyclin D1.

We have begun choosing a set of breast cancer cell lines to analyze for cyclin D1 and p21 expression. As part of this task, we needed a relatively "normal" breast epithelial cell line for comparison. We have chosen the MCF10A line because it is an immortal cell line that arose spontaneously from benign breast tissue without viral or chemical intervention (some of which can disrupt cell cycle regulation). Although MCF10A cells obtained originally from the American Type Tissue Collection (ATCC) were already transformed, we have more recently obtained normal MCF10A cells. In our hands the cells exhibit a requirement for mitogens and adhesion for proliferation. Their doubling time is approximately 24 to 28 hrs. Asynchronous proliferating MCF10A cells exhibit low to moderate but easily detectable levels of cyclin D1. The levels of p21 are undetectable. Furthermore, we have determined that serum starvation for 3 days synchronizes the cells in G0 (Fig 2). We will subsequently begin comparisons

with malignant breast cancer cell lines with regard to cyclin D1 and p21 expression levels.

**Aim 4:** Examine the relative expression of cyclin D1 and cyclin dependent kinase inhibitors in a series of breast cancer biopsies.

Task 1. Develop and quantify the immunohistochemical procedures for the analysis of breast cancer biopsies. Confirm that the antibodies can detect protein expression in formalin fixed, paraffin-embedded tissue.

We described the procedure for staining cell pellet sections for cyclin D1 and p27 in the last report. We are currently determining the optimal conditions for p21 low and high expression levels and have prepared cell pellets to analyze optimal conditions for p21 staining (see task 2).

Task 2: Obtain high- and low-expression controls for cyclin D1, p21, and p27 antibodies by preparing blocks from cell lines which over- or under-express the cognate protein.

We described the preparation and staining of the positive and negative controls for cyclin D1 and p27 in the last report. Since the p21 antibody is species-specific, mouse fibroblasts cannot be used to obtain the controls for optimization conditions. Using breast epithelial cells, we have determined that cells starved for 2 days completely suppress p21 expression. Conversely, synchronized cells that are stimulated for 2 to 4 hours, maximally express p21 (Fig 3). Using these conditions, we have prepared cell pellets for high- and low-expression controls for p21.

Task 3. Identify human breast cancer tissue specimens which fulfill the requirements for good and poor prognostic factors. Prepare tissue sections of these specimens in a blinded fashion for evaluation.

Dr. Mies has chosen 22 specimens of human breast cancer tissue from the tissue bank at the University of Miami. These include both good and bad prognostic samples but are blinded until the completion of the study.

Task 4. Perform the immunohistochemical staining of the selected specimens using the characterized antibodies. Analyze and quantify the relative expression levels of cyclin D1, p21 and p27 in each biopsy.

Dr. Mies has performed the immunohistochemical staining for cyclin D1 and p27 on the specimens chosen in Task 3. Staining for cyclin D1 has proven to be somewhat difficult because high levels of background staining have made interpretation difficult. After repeating with various reagents, she has obtained more optimal and reproducible staining results. Dr. Mies has also stained the sections for MIB-1/Ki67, an S-phase marker. The results for the



immunohistochemical stains thus far are shown in Table 1 and a representative specimen demonstrating these stains is shown in Fig 4. Once the optimization procedures for p21 staining are determined, these sections will be also be analyzed for p21 expression levels.

Following complete analysis of the results, the clinical correlation and prognostic factors will be unblinded to determine if there is a correlation between expression levels and prognosis.

## **KEY RESEARCH ACCOMPLISHMENTS**

- A tetracycline-regulated cyclin D1 construct has been successfully cloned into mouse embryo fibroblasts and is stable in cell culture. Cyclin D1 expression is normally regulated by adhesion in two of these clones and appropriately regulated by tetracycline in all.
- Utilizing these clones, extensive characterization of the effect of cyclin D1 on p21 expression has been performed. It appears that in mouse embryo fibroblasts, there is no compensatory increase in p21 levels despite significant overexpression of cyclin D1.
- We have characterized the conditions for regulation of cyclin D1, p27 and p21 in MCF10A cells. The characterization of expression levels of cyclin D1 and p21 in breast cancer cells is underway.
- Optimization of immunohistochemical staining procedures using cyclin D1 and p27 antibodies has been completed. Optimization for p21 antibodies is underway.
- Two groups of human breast cancer specimens which exhibit good and poor prognostic factors, respectively, has been selected and stained in a blinded fashion for cyclin D1 and p27.

## **REPORTABLE OUTCOMES**

We have developed MEF cells that are stably transfected with a tetracycline-regulated cyclin D1 construct that are adhesion-dependent and appropriately responsive to tetracycline.

## **CONCLUSIONS ("so what section")**

1. Mouse embryo fibroblasts that stably express a tetracycline-regulated cyclin D1 construct have been successfully established. This system was chosen because p21 and p27 knock-outs were generated in MEFs. Despite

significant overexpression of cyclin D1 in these cells, there was no compensatory upregulation of p21 in MEFs. This is in contrast to the ability of NIH-3T3 cells to upregulate p21 in response to cyclin D1 overexpression. This result precludes the ability to analyze the effect of such interaction on tumor formation of these cells in nude mice. Possible explanations include the acquisition of p53 mutations in MEFs which may interfere with their ability to upregulate p21 as compared to cells with wild-type p53. We plan to use NIH-3T3 cells to determine if the induction of p21 is due to changes in its mRNA expression.

2. A series of human breast cancer specimens have been analyzed for cyclin D1, p27, and MIB-1/Ki67 levels. Analysis of p21 levels will follow completion of optimization of the staining procedure. Following complete analysis of the results, the clinical correlation and prognostic factors will be unblinded to determine if there is a correlation between expression levels and prognosis.

## REFERENCES

1. Lammie GA, Fantl V, Smith R, Shuuring E, Brookes S, Michalides R, Dickson C, Arnold A, and Peters G (1991) D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. *Oncogene* 6:: 439-444.
2. Schuuring E, Verhoeven E, Mooi WJ, and Michalides RJAM (1992) Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. *Oncogene* 7: 355-361.
3. Theillet C, Adane J, Szepetowski P, Simon M-P, Jeanteur P, Birnbaum D, and Gaudray P (1990) BCL-1 participates in the 11q13 amplification found in breast cancer. *Oncogene* 5: 147-149.
4. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, and Bartek J (1994) Cyclin D1 protein expression and function in human breast cancer. *Int. J. Cancer* 57:353-361.
5. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, and Sutherland RL (1993) Expression and amplification of cyclin genes in human breast cancer. *Oncogene* 8: 2127-2133.
6. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, and Schmidt EV (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. *Nature* 369: 669-671.
7. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, and Roberts JM. (1997) Expression of cell-cycle regulators p27kip1 and cyclin E,

alone and in combination, correlate with survival in young breast cancer patients. *Nature Medicine* 3: 222-225.

8. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, and Slingerland JM. (1997) Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. *Nature Medicine* 3: 227-230.
9. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, and Pagano M. (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. *Nature Medicine* 3: 231-234.
10. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, and Lu X (1997) High level expression of p27kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27kip1 and degree of malignancy in human breast and colorectal cancers. *Proc. Natl. Acad. Sci.* 94: 6380-6385.
11. Jiang M, Shao Z-M, Wu J, Lu J-S, Yu L-M, Yuan J-D, Han Q-X, Shen Z-Z, and Fontana JA (1997) p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. *Int. J. Cancer* 74: 529-534.
12. Polyak K, Kato J-y, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. (1994) p27kip1, a cyclin-cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. *Genes and Development* 8: 9-22.
13. Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, and Massague J. (1994) Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. *Cell* 78: 59-66.
14. Toyoshima H and Hunter T. (1994) p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. *Cell* 78: 67-74.
15. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M-H, Massague J, Crabtree GR, and Roberts JM. (1994) Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. *Nature* 372: 570-573.
16. Sherr CJ and Roberts JR (1995) Inhibitors of mammalian cyclin-dependent kinases. *Genes and Dev.* 9: 1149-1163.
17. Zhu X, Ohtsubo M, Bohmer RM, Roberts JM, and Assoian RK. (1996) Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. *J Cell Biol.* 133: 391-403.

18. Fang F, Orend G, Watanabe N, Hunter T, and Ruoslahti E (1996) Dependence of cyclin E-cdk2 kinase activity on cell anchorage. *Science* 271: 499-502.
19. Han EK, Sgambato A, Jiang W, Zhang Y, Santella RM, Doki Y, Cacace AM, Schieren I, and Weinstein IB (1995) Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. *Oncogene* 10: 953-961.
20. Han EK, Begemann M, Sgambato A, Soh J-W, Doki Y, Xing W-Q, Liu W, and Weinstein IB (1996) Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. *Cell Growth and Diff.* 7: 699-710.

## FIGURES


**Figure 1.** Control (untransfected) MEFs and MEFs stably expressing tetracycline-regulated cyclin D1 were serum-starved into G0, trypsinized, suspended in DMEM, 5% FCS and replated in monolayer (Mn) or suspension (Sp) in the presence (+) and absence (-) of tetracycline for 18 hr. Cells were collected and lysed. Equal amounts of protein from each cell lysate was fractionated on an SDS gel, transferred to nitrocellulose and immunoblotted with antibodies specific for cyclin D1, p21 and cdk4 (protein loading control).

**Figure 2.** Synchronization of MCF10A cells by serum and growth factor deprivation Subconfluent cells were seeded in replete media the day prior to starvation to reach 70-80% confluency on Day 0. Cells were washed and the media replaced with DME/F12 without growth factors and serum. Cells were harvested after the indicated number of days and lysates separated by SDS-PAGE. The levels of cyclin D1, cyclin A, p27, and cdk4 (as a loading control) were determined.


**Figure 3.** p21 induction in MCF10A cells. Cells were synchronized in G0 by serum and growth factor deprivation followed by stimulation with 10% FCS and EGF. Cells were collected at the indicated time points and lysates separated by SDS-PAGE. The levels of p21 and actin (as a loading control) were determined by specific antibodies.

**Figure 4.** Example of an invasive lobular carcinoma immunohistochemically stained for cyclin D1, p21 and MIB-1/Ki67. a) Cyclin D1 stains the nuclei of the majority of infiltrating carcinoma cells dark brown-black; a central benign terminal duct-lobular unit is negative. b) The majority of nuclei are positive for p27. c) anti-MIB-1/Ki67 darkly stains a small number of nuclei in the same carcinoma. (Fast green counterstain; original magnification 200x.)






**Figure 2**



**Figure 3**



**Figure 4**



## CYCLIN D1, P27 &amp; Ki67 IN INVASIVE LOBULAR CARCINOMA

SURGICAL MORPHOLOGICAL		SUBTYPE	CYCLIN D 1			P27		PENDING P 21		MIB-Y	Ki 67
CASE #	PATH #										
		C= Classical V= Variant P= Pleomorphic									
1		C									
	Invasive	Present	1 +			3 +				1 +	
	In Situ	DCIS Present	1 +			3 +				1 +	
		LCIS Absent	--			--				DCIS	> ILC
2		C									
	Invasive	Present	1 +			3 +				0	
	In Situ	Part of one TDLU	0			NA				NA	
3		C									
		P									
	Invasive	Present	1 +			2 +				1 +	
	In Situ	LCIS Present	2 +			3 +				1 +	
4		P									
	Invasive	Present	2 +			2 +				0	
	In Situ	Present	0			2 +				0	
5		C									
	Invasive	Present	TI			3 +				1 +	
	In Situ	Present	TI			3 +				0	
6		V= Tubulobular									
	Invasive	Present	0			0				Low 1 +	
	In Situ	DCIS Present	0			1 +				1 +	
		LCIS Absent	--			--					
7		P									
	Invasive	Present	2 +			2 +*				1 +	
	In Situ	Present	1 +			3 +				0	
There is a large cell component in the invasive lobular component in which p27 is (-) or very low. Strong (+) staining is seen only in the smaller cells.											
Definitions: TI = Technically Inadequate; repeat											
Staining Score: 1+ =1-33% cells positive											
2+ = 34-66% cells positive											
3+ = 67-100% cells positive											
0 = Negative											
NA = Not apparent on the section											

## CYCLIN D1, P27 &amp; Ki67 IN INVASIVE LOBULAR CARCINOMA

SURGICAL		MORPHOLOGICAL	CYCLIN D 1			P27		PENDING P 21		MIB-Y	KI 67
CASE #	PATH #	SUBTYPE									
		C= Classical V= Variant P= Pleomorphic									
8		C									
	Invasive	Present	3 +			1 +				2 +	
	In Situ	Absent	--			--				--	
9		C									
	Invasive	Present	1 +			1 +				2 +	
	In Situ	DCIS Present	1 +			1 +				1 +	
		LCIS Present	1 +			1 +				NA	
10		C									
	Invasive	Present	TI			1 +				1 +	
	In Situ	Absent	TI			--				--	
11		P									
	Invasive	Present	3 +			1 +				1 +	
	In Situ	Absent	--								
12		C									
	Invasive	Present	3+			3 +				2 +	
	In Situ	Absent	--			--				--	
13		P									
	Invasive	Present	1 +			3 +				1 +	
	In Situ	Absent	--			--				--	
14		C									
	Invasive	Present	3 +			rare +				TI	
	In Situ	Present	0								
15		C									
	Invasive	Present	3 +			1 +				1 +	
	In Situ	DCIS Present	3+			1 +				1 +	
Definitions: TI = Technically Inadequate; repeate Staining Score: 1+ =1-33% cells positive 2+ = 34-66% cells positive 3+ = 67-100% cells positive 0 = Negative NA = Not aapparent on the section											

## CYCLIN D1, P27 &amp; Ki67 IN INVASIVE LOBULAR CARCINOMA

SURGICAL MORPHOLOGICAL			CYCLIN D 1			P27		PENDING P 21		MIB-Y		KI 67
CASE #	PATH #	SUBTYPE										
		C= Classical V= Variant P= Pleomorphic										
16		C										
	Invasive	Present		TI		3+						TI
	In Situ	Present		TI		TI						TI
17		V										
	Invasive	Present		1 +		1 +					1 +	
	In Situ	Absent										
18		C										
	Invasive	Present		3 +		1 +					1 +	
	In Situ	Absent		NA		NA					NA	
19		C										
	Invasive	Present		3 +		1 +					1 +	
	In Situ	Absent		--		--					--	
20		C										
	Invasive	Present		2 +		2 +					0	
	In Situ	DCIS Present		1 +		2 +					1 +	
		LCIS Present		0		2 +						
21		C										
	Invasive	Present		3 +		3 +					1 +	
	In Situ	Present		3 +								
22		C										
	Invasive	Present		1 +		1 +					2 +	
	In Situ	Absent		--		1 +					NA	